The broad spectrum of activity of ciprofloxacin makes it an ideal drug for the prophylaxis of bacterial infections in patients undergoing high-dose chemotherapy (HDC) with autologous stem cell rescue. We present two cases of ciprofloxacin-associated acute renal failure (ARF) in patients undergoing HDC. Maintaining a high index of suspicion for this complication will allow a prompt diagnosis, with discontinuation of the drug usually resulting in a reversal of renal failure. Renal biopsy usually reveals changes compatible with interstitial nephritis, but is not always possible in these patients due to severe thrombocytopenia following HDC. A brief course of steroid therapy may be beneficial although the role of glucocorticoids is difficult to ascertain in the absence of data regarding its efficiency in this clinical setting. Keywords: ciprofloxacin; nephrotoxicity; high-dose chemotherapy; stem cell transplantation Prophylactic antibiotics following high-dose chemotherapy (HDC) have become routine, decreasing febrile episodes and greatly reducing the mortality from bacterial infections, primarily gram-negative sepsis.
Prophylactic antibiotics following high-dose chemotherapy (HDC) have become routine, decreasing febrile episodes and greatly reducing the mortality from bacterial infections, primarily gram-negative sepsis. 1 The use of prophylactic oral ciprofloxacin has greatly facilitated the outpatient management of patients undergoing HDC. We report two cases of ciproloxacin-associated nephrotoxicity in patients undergoing HDC.
Case reports

Case 1
A 53-year-old man with breast cancer was treated with HDC (cyclophosphamide 6000 mg/m acyclovir 400 mg three times a day were started on the day of stem cell reinfusion. On day 8 he developed febrile neutropenia and was hospitalized. Vancomycin 30 mg/kg/day and ceftriaxone 2 g/day intravenously were added and ciprofloxacin was continued. Rifampin was stopped. All cultures were negative. Clinically, the patient was not septic, hypovolemic or dehydrated and had good urine output. On admission his creatinine was 1.5 mg/dl, and increased to 4.8 mg/dl the following day. Urinalysis revealed few white blood cells and no eosinophils. Renal ultrasound showed neither obstruction nor hydroephrosis. Ciprofloxacininduced nephritis was diagnosed; all antibiotics were discontinued, and intravenous solumedrol 120 mg/day was started. The creatinine peaked the following day to 6.0 mg/dl, and returned to normal on the third day.
Case 2
A 56-year-old woman with multiple myeloma underwent HDC with melphalan 140 mg/m 2 . Prophylactic oral ciprofloxacin 750 mg and rifampin 300 twice daily were begun on the day of stem cell reinfusion. Her creatinine was 0.6 mg/dl. On day 9 she developed a fever and was begun on intravenous vancomycin 30 mg/kg/day and ceftriaxone 2 g/day, with continuation of ciprofloxacin. Rifampin was discontinued. All cultures were negative. The following day the creatinine rose to 3.3 mg/dl and she developed oliguria without hypotension or hypovolemia. She had received only one dose of vancomycin and ceftriaxone. Urinalysis showed few white blood cells. Renal ultrasound showed no obstruction or hydronephrosis. All antibiotics were discontinued, and she was treated with intravenous solumedrol 60 mg/day. The creatinine peaked the following day to 4.5 mg/dl and returned to normal on the fourth day.
Discussion
The incidence of adverse reactions to ciprofloxacin is about 5.8%, commonly gastrointestinal disturbances and central nervous system reactions. 2 Mild, transient elevations in serum creatinine have been reported in some patients. Several case reports have recently described ciprofloxacinassociated acute renal failure (ARF) in cancer patients. 3 To our knowledge, this has not been reported in patients undergoing HDC. Although both our patients received other drugs, in each case the time course suggests that ciprofloxacin is the drug most likely to be responsible for ARF. In the first patient, a rise in the serum creatinine was noted prior to the administration of vancomycin. This patient had received acyclovir for a week prior to the development of ARF. However, acyclovir is usually associated with intratubular precipitation of the drug and resultant crystal nephropathy when the maximum solubility of free drug has been exceeded. The second patient received only one dose of vancomycin a few hours prior to the elevation in the serum creatinine; this drug is therefore unlikely to have been the cause of the ARF. Both patients had normal underlying kidney function prior to HDC. Neither patient had any significant degree of hypovolemia or hypotension, and there was no evidence of sepsis. The chemotherapy used in these two patients does not commonly cause RF, although carboplatin can cause a mild elevation in the serum creatinine level. The second patient with multiple myeloma may have had underlying subclinical renal impairment.
Fluoroquinolones are believed to induce interstitial nephritis, sometimes associated with phenomena suggesting an immunological reaction, eg fever, rash and eosinophila.
